Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 5.96B +132.6% |
| Revenue (ttm) | 274.48M +51.2% |
| Net Income | 153.56M |
| EPS | 7.50 |
| Shares Out | 19.81M |
| PE Ratio | 40.00 |
| Forward PE | 53.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 306,874 |
| Open | 294.08 |
| Previous Close | 292.04 |
| Day's Range | 294.08 - 301.15 |
| 52-Week Range | 131.67 - 326.63 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 327.40 (+8.91%) |
| Earnings Date | Aug 6, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $327.4, which is an increase of 8.91% from the latest price.
News
Ligand price target raised to $326 from $285 at Oppenheimer
Oppenheimer raised the firm’s price target on Ligand (LGND) to $326 from $285 and keeps an Outperform rating on the shares. The firm says its new model reflects the Xoma…
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 202...
Ligand resumed with a Buy at Citi
Citi resumed coverage of Ligand (LGND) with a Buy rating and $387 price target following the close of the Xoma acquisition. The firm views the deal as “highly compelling” and…
Ligand price target raised to $345 from $330 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt raised the firm’s price target on Ligand (LGND) to $345 from $330 and keeps a Buy rating on the shares. Following investor meetings, the firm notes…
Ligand price target raised to $335 from $275 at Benchmark
Benchmark analyst Robert Wasserman raised the firm’s price target on Ligand (LGND) to $335 from $275 and keeps a Buy rating on the shares after the company announced the completion…
Ligand price target raised to $340 from $262 at RBC Capital
RBC Capital raised the firm’s price target on Ligand (LGND) to $340 from $262 and keeps an Outperform rating on the shares. The firm is updating its model and price…
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating...
XOMA Royalty Announces Closing of Its Acquisition by Ligand
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisitio...
Ligand price target raised to $388 from $266 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $388 from $266 and keeps a Buy rating on the shares. Despite strong share performance, Ligand’s growth…
Ligand price target raised to $332 from $255 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Ligand (LGND) to $332 from $255 and keeps a Buy rating on the shares. The firm’s estimates now incorporate expanded…
Ligand Announces Closing of Convertible Senior Notes Offering
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...
Ligand prices upsized $625M convertible senior note offering
Ligand (LGND) Pharmaceuticals announced the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 in a private placement to persons reasonably believed to be q...
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...
Ligand files to sell $550M of convertible senior notes due 2031
Ligand (LGND) Pharmaceuticals announced its intention to offer $550M aggregate principal amount of convertible senior notes due 2031 in a private placement to persons reasonably believed to be qualifi...
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offse...
Ligand Announces 2026 Investor Day in New York City
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 1...
Ligand price target raised to $266 from $263 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $266 from $263 and keeps a Buy rating on the shares after Travere Therapeutics (TVTX) announced a…
Ligand to Participate in June Investor Conferences
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Ligand reports Q1 adjusted EPS $1.63, consensus $1.80
Reports Q1 revenue $51.72M, consensus $58.86M. “The first few months of 2026 have already proven to be highly productive and transformative for Ligand (LGND),” said Todd Davis, CEO of Ligand.
Ligand backs FY26 adjusted EPS view $8.50-$9.50, consensus $9.21
Backs FY26 revenue view $270M-$310M, consensus $288.97M. The company said, “Ligand (LGND) is reaffirming its 2026 full-year financial guidance, which was raised on April 27, 2026 in connection with th...
Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% royalty revenue and 23% adjusted EPS growth year-over-year, driven by portfolio expansion and the strategic shift to royalty aggregation. The XOMA Royalty acquisition is expected to be immediately accretive, further diversifying assets and accelerating long-term growth.
Ligand Pharmaceuticals Earnings release: Q1 2026
Ligand Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q1 2026
Ligand Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ligand Pharmaceuticals Quarterly report: Q1 2026
Ligand Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.